“…The kinetics of endogenous substrates for nucleoside transporters has been extensively studied, predominately with ENT1 (Boleti et al, 1997;Ward et al, 2000;Bone and Hammond, 2007;Boswell-Casteel and Hays, 2017;Miller et al, 2020;Miller et al, 2021) and recent advancements include the determination of the ENT1 crystal structure bound to two nontransported ENT1 inhibitors, 6-nitrobenzylthioinosine and dilazep (Wright and Lee, 2019), but further research is necessary to understand the roles that human ENT1 and ENT2 play in the pharmacokinetics of currently prescribed therapeutics and therapeutics currently in development. Identifying, predicting and validating drug interactions with these transporters may inform and facilitate the drug development process for new chemotherapeutics, antivirals, and male contraceptives and fertility agents (Mruk et al, 2011;Ekins et al, 2012;Pastor-Anglada and Pérez-Torras, 2018;Ekins et al, 2019;Rehan et al, 2019).…”